Dual antiplatelet therapy after coronary stenting

Expert Opinion on Pharmacotherapy

Volumn 17, Issue 13, 2016, Pages 1775-1787

  Park, Yongwhi ^a,b   Franchi, Francesco ^a   Rollini, Fabiana ^a   Angiolillo, Dominick J ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b Gyeongsang National University School of Medicine   (South Korea)

Author keywords

Antiplatelet therapy; coronary artery disease; coronary stent; duration of antiplatelet therapy

Indexed keywords

ANTITHROMBOCYTIC AGENT; ACETYLSALICYLIC ACID;

ACUTE CORONARY SYNDROME; BLEEDING; CLINICAL FEATURE; CLINICAL PRACTICE; CORONARY STENTING; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; DUAL ANTIPLATELET THERAPY; EVEROLIMUS ELUTING CORONARY STENT; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; META ANALYSIS (TOPIC); PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIROLIMUS ELUTING CORONARY STENT; TREATMENT DURATION; ADVERSE EFFECTS; CHEMICALLY INDUCED; PERCUTANEOUS CORONARY INTERVENTION; PROCEDURES; TIME FACTOR;

ASPIRIN; DRUG-ELUTING STENTS; HEMORRHAGE; HUMANS; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME FACTORS;

EID: 84983507532     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1080/14656566.2016.1202924     Document Type: Review

References (72)

1. D.J.Angiolillo The evolution of antiplatelet therapy in the treatment of acute coronary syndromes:from aspirin to the present day. Drugs. 2012;72:2087–16.
2. G.N.Levine, E.R.Bates, J.C.Blankenship, et al. ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol. 2011;58:e44–122.
3. S.Windecker, P.Kolh, F.Alfonso, et al. ESC/EACTS Guidelines on myocardial revascularization:The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014;35:2541–2619.
4. E.A.Amsterdam, N.K.Wenger, R.G.Brindis, et al. AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;64:e139–228.
5. M.Roffi, C.Patrono, J.P.Collet, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation:Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016;37:267–315.
6. G.N.Levine, E.R.Bates, J.A.Bittl, et al. ACC/AHA Guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease:A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2016 [cited 23Mar 2016]. doi:10.1016/j.jacc.2016.03.513.• This guideline provides the most updated recommendations on duration of DAPT after newer-generation drug-eluting stent implantation.
7. F.Franchi, D.J.Angiolillo. Novel antiplatelet agents in acute coronary syndrome. Nat Rev Cardiol. 2015;12:30–47.
8. S.D.Wiviott, E.Braunwald, C.H.McCabe, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001–2015.
9. L.Wallentin, R.C.Becker, A.Budaj, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045–1057.
10. W.Fan, S.Plent, J.Prats, et al. Trends in P2Y12 inhibitor use in patients referred for invasive evaluation of coronary artery disease in contemporary US practice. Am J Cardiol. 2016;117:1439–1443.
11. S.Yusuf, F.Zhao, S.R.Mehta, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494–502.
12. S.R.Mehta, S.Yusuf, R.J.Peters, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention:the PCI-CURE study. Lancet. 2001;358:527–533.
13. S.R.Steinhubl, P.B.Berger, J.T.Mann3rd, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention:a randomized controlled trial. JAMA. 2002;288:2411–2420.
14. T.Jernberg, P.Hasvold, M.Henriksson, et al. Cardiovascular risk in post-myocardial infarction patients:nationwide real world data demonstrate the importance of a long-term perspective. Eur Heart J. 2015;36:1163–1170.
15. B.Lagerqvist, S.K.James, U.Stenestrand, et al. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med. 2007;356:1009–1019.
16. J.Daemen, P.Wenaweser, K.Tsuchida, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice:data from a large two-institutional cohort study. Lancet. 2007;369:667–678.
17. T.Palmerini, G.Biondi-Zoccai, D.Della Riva, et al. Stent thrombosis with drug-eluting stents:is the paradigm shifting? J Am Coll Cardiol. 2013;62:1915–1921.
18. T.Tada, R.A.Byrne, I.Simunovic, et al. Risk of stent thrombosis among bare-metal stents, first-generation drug-eluting stents, and second-generation drug-eluting stents:results from a registry of 18,334 patients. JACC Cardiovasc Interv. 2013;6:1267–1274.
19. D.R.HolmesJr, D.J.Kereiakes, S.Garg, et al. Stent thrombosis. J Am Coll Cardiol. 2010;56:1357–1365.
20. F.Franchi, F.Rollini, Y.Park, et al. Novel antiplatelet agents:the current state and what is coming down the pike. Prog Cardiovasc Dis. 2015;58:267–277.
21. D.J.Angiolillo, J.L.Ferreiro. Antiplatelet and anticoagulant therapy for atherothrombotic disease:the role of current and emerging agents. Am J Cardiovasc Drugs. 2013;13:233–250.
22. D.Capodanno, D.J.Angiolillo. Management of antiplatelet and anticoagulant therapy in patients with atrial fibrillation in the setting of acute coronary syndromes or percutaneous coronary interventions. Circ Cardiovasc Interv. 2014;7:113–124.
23. D.P.Faxon, J.W.Eikelboom, P.B.Berger, et al. Consensus document:antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective. Thromb Haemost. 2011;106:572–584.
24. G.Y.Lip, S.Windecker, K.Huber, et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions:a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Eur Heart J. 2014;35:3155–3179.
25. M.E.Bertrand, H.J.Rupprecht, P.Urban, et al. CLASSICS Investigators. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting:the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation. 2000;102:624–629.
26. D.J.Angiolillo, A.Fernandez-Ortiz, E.Bernardo, et al. Variability in individual responsiveness to clopidogrel:clinical implications, management, and future perspectives. J Am Coll Cardiol. 2007;49:1505–1516.
27. M.T.Roe, P.W.Armstrong, K.A.Fox, et al. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med. 2012;367:1297–1309.
28. H.C.Gwon, J.Y.Hahn, K.W.Park, et al. Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents:the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study. Circulation. 2012;125:505–513.
29. A.Colombo, A.Chieffo, A.Frasheri, et al. Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy:the SECURITY randomized clinical trial. J Am Coll Cardiol. 2014;64:2086–2097.
30. S.Schulz-Schüpke, R.A.Byrne, J.M.Ten Berg, et al. ISAR-SAFE:a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting. Eur Heart J. 2015;36:1252–1263.
31. B.K.Kim, M.K.Hong, D.H.Shin, et al. A new strategy for discontinuation of dual antiplatelet therapy:the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation). J Am Coll Cardiol. 2012;60:1340–1348.
32. F.Feres, R.A.Costa, A.Abizaid, et al. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents:the OPTIMIZE randomized trial. JAMA. 2013;310:2510–2522.
33. C.W.Lee, J.M.Ahn, D.W.Park, et al. Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation:a randomized, controlled trial. Circulation. 2014;129:304–312.
34. J.P.Collet, J.Silvain, O.Barthélémy, et al. Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption):a randomised trial. Lancet. 2014;384:1577–1585.
35. G.Helft, P.G.Steg, C.Le Feuvre, et al. Stopping or continuing clopidogrel 12 months after drug-eluting stent placement:the OPTIDUAL randomized trial. Eur Heart J. 2016;37:365–374.
36. M.Valgimigli, G.Campo, M.Monti, et al. Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting:a randomized multicenter trial. Circulation. 2012;125:2015–2026.
37. M.Gilard, P.Barragan, A.A.Noryani, et al. 6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin:the randomized, multicenter ITALIC trial. J Am Coll Cardiol. 2015;65:777–786.
38. L.Mauri, D.J.Kereiakes, R.W.Yeh, et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014;371:2155–2166.
39. M.P.Bonaca, D.L.Bhatt, M.Cohen, et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015;372:1791–1800.
40. J.A.Bittl, U.Baber, S.M.Bradley, et al. Duration of dual antiplatelet therapy:a systematic review for the ACC/AHA Guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease:A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2016 [cited 22Mar 2016]. doi:10.1016/j.jacc.2016.03.512•• This meta-analysis is a comprehensive analysis of randomized controlled studies on duration of DAPT. The recommendations on duration of DAPT made by the recent guidelines were guided by this analysis.
41. T.Palmerini, D.Sangiorgi, M.Valgimigli, et al. Short- versus long-term dual antiplatelet therapy after drug-eluting stent implantation:an individual patient data pairwise and network meta-analysis. J Am Coll Cardiol. 2015;65:1092–1102.
42. G.Giustino, U.Baber, S.Sartori, et al. Duration of dual antiplatelet therapy after drug-eluting stent implantation:a systematic review and meta-analysis of randomized controlled trials. J Am Coll Cardiol. 2015;65:1298–1310.
43. M.Valgimigli, M.Borghesi, M.Tebaldi, et al. Should duration of dual antiplatelet therapy depend on the type and/or potency of implanted stent? A pre-specified analysis from the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY). Eur Heart J. 2013;34:909–919.
44. J.B.Hermiller, M.W.Krucoff, D.J.Kereiakes, et al. Benefits and risks of extended dual antiplatelet therapy after everolimus-eluting stents. JACC Cardiovasc Interv. 2016;9:138–147.
45. D.J.Kereiakes, R.W.Yeh, J.M.Massaro, et al. Antiplatelet therapy duration following bare metal or drug-eluting coronary stents:the dual antiplatelet therapy randomized clinical trial. JAMA. 2015;313:1113–1121.
46. R.W.Yeh, D.J.Kereiakes, P.G.Steg, et al. Benefits and risks of extended duration dual antiplatelet therapy after PCI in patients with and without acute myocardial infarction. J Am Coll Cardiol. 2015;65:2211–2221.
47. S.Elmariah, L.Mauri, G.Doros, et al. Extended duration dual antiplatelet therapy and mortality:a systematic review and meta-analysis. Lancet. 2015;385:792–798.
48. FDA drug safety communication:FDA review finds long-term treatment with blood-thinning medicine Plavix (clopidogrel) does not change risk of death. [cited 28 Apr 2016]. Available from:http://www.fda.gov/Drugs/DrugSafety/ucm471286.htm
49. P.Roy, L.Bonello, R.Torguson, et al. Impact of “nuisance” bleeding on clopidogrel compliance in patients undergoing intracoronary drug-eluting stent implantation. Am J Cardiol. 2008;102:1614–1617.
50. D.L.Bhatt, K.A.Fox, W.Hacke, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354:1706–1717.
51. D.L.Bhatt, M.D.Flather, W.Hacke, et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol. 2007;49:1982–1988.
52. M.P.Bonaca, D.L.Bhatt, P.G.Steg, et al. Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction:insights from PEGASUS-TIMI 54. Eur Heart J. 2016;37:1133–1142.
53. J.A.Udell, M.P.Bonaca, J.P.Collet, et al. Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction:a collaborative meta-analysis of randomized trials. Eur Heart J. 2016;37:390–399.
54. C.B.Granger, R.J.Goldberg, O.Dabbous, et al. Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med. 2003;163:2345–2353.
55. K.A.Eagle, M.J.Lim, O.H.Dabbous, et al. A validated prediction model for all forms of acute coronary syndrome:estimating the risk of 6- month postdischarge death in an international registry. JAMA. 2004;291:2727–2733.
56. S.Subherwal, R.G.Bach, A.Y.Chen, et al. Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction:the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines) bleeding score. Circulation. 2009;119:1873–1882.
57. R.Mehran, S.J.Pocock, E.Nikolsky, et al. A risk score to predict bleeding in patients with acute coronary syndromes. J Am Coll Cardiol. 2010;55:2556–2566.
58. R.W.Yeh, E.A.Secemsky, D.J.Kereiakes, et al. Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention. JAMA. 2016;315:1735–1749.•• The DAPT score was developed to assess long-term ischemic and bleeding risks in patients with prolonged DAPT. This scoring system may be a useful tool for decision making about whether DAPT could be continued or not.
59. U.Baber, R.Mehran, G.Giustino, et al. Coronary thrombosis and major bleeding after PCI with drug-eluting stents:risk scores from PARIS. J Am Coll Cardiol. 2016;67:2224–2234.
60. G.Campo, M.Tebaldi, P.3.Vranckx, et al. Short- versus long-term duration of dual antiplatelet therapy in patients treated for in-stent restenosis:a PRODIGY trial substudy (prolonging dual antiplatelet treatment after grading stent-induced intimal hyperplasia). J Am Coll Cardiol. 2014;63:506–512.
61. M.Valgimigli, A.Patialiakas, A.Thury, et al. Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates. J Am Coll Cardiol. 2015;65:805–815.
62. S.Ariotti, M.Adamo, F.Costa, et al. Is bare-metal stent implantation still justifiable in high bleeding risk patients undergoing percutaneous coronary intervention? a pre-specified analysis from the ZEUS trial. JACC Cardiovasc Interv. 2016;9:426–436.
63. D.Capodanno, D.J.Angiolillo. Antithrombotic therapy in the elderly. J Am Coll Cardiol. 2010;56:1683–1692.
64. D.Capodanno, D.J.Angiolillo. Antithrombotic therapy in patients with chronic kidney disease. Circulation. 2012;125:2649–2661.
65. J.Wiebe, H.M.Nef, C.W.Hamm. Current status of bioresorbable scaffolds in the treatment of coronary artery disease. J Am Coll Cardiol. 2014;64:2541–2551.
66. S.Cassese, R.A.Byrne, G.Ndrepepa, et al. Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents:a meta-analysis of randomised controlled trials. Lancet. 2016;387:537–544.
67. G.W.Stone, R.Gao, T.Kimura, et al. 1-year outcomes with the Absorb bioresorbable scaffold in patients with coronary artery disease:a patient-level, pooled meta-analysis. Lancet. 2016;387:1277–1289.
68. M.J.Lipinski, R.O.Escarcega, N.C.Baker, et al. Scaffold thrombosis after percutaneous coronary intervention with ABSORB bioresorbable vascular scaffold:a systematic review and meta-analysis. JACC Cardiovasc Interv. 2016;9:12–24.
69. X.L.Zhang, L.Zhu, Z.H.Wei, et al. Comparative efficacy and safety of everolimus-eluting bioresorbable scaffold versus everolimus-eluting metallic stents:a systematic review and meta-analysis. Ann Intern Med. 2016 [cited 5Apr 2016]. doi:10.7326/M16-0006.
70. L.Räber, S.Brugaletta, K.Yamaji, et al. Very late scaffold thrombosis:intracoronary imaging and histopathological and spectroscopic findings. J Am Coll Cardiol. 2015;66:1901–1914.
71. D.Capodanno, M.Joner, M.Zimarino. What about the risk of thrombosis with bioresorbable scaffolds? EuroIntervention. 2015;11(Suppl V):V181–184.
72. D.Capodanno, T.Gori, H.Nef, et al. Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice:early and midterm outcomes from the European multicentre GHOST-EU registry. EuroIntervention. 2015;10:1144–1153.